Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

peptide conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Formyl Peptide Receptor (FPR) (1) Peptide-Drug Conjugates (PDCs) (13) ADC Linker (8) ADC Payload (7) Adrenergic Receptor (1) Amino Acid Derivatives (2) Aminopeptidase (2) Antibody-Drug Conjugates (ADCs) (4) Apoptosis (6) Autophagy (1) Bacterial (12) Biochemical Assay Reagents (77) Bombesin Receptor (1) Calcium Channel (1) Carbonic Anhydrase (1) Casein Kinase (1) CD47 (2) CXCR (5) DNA/RNA Synthesis (3) Drug Derivative (9) Drug Intermediate (6) Drug-Linker Conjugates for ADC (27) E-Selectin (1) E1/E2/E3 Enzyme (1) EGFR (7) Endogenous Metabolite (7) Ephrin Receptor (1) Epigenetic Reader Domain (2) Eukaryotic Initiation Factor (eIF) (1) Exosomes (4) FAP (2) FGFR (1) Fluorescent Dye (19) Folate Receptor (FR) (3) G-quadruplex (1) GLP Receptor (2) Glucocorticoid Receptor (2) HBV (1) HDAC (2) HIV (4) HSP (2) IFNAR (1) Influenza Virus (1) Insulin Receptor (1) Integrin (6) Isotope-Labeled Compounds (8) LDLR (2) Liposome (19) LYTACs (1) MARCKS (1) Microtubule/Tubulin (6) Mitochondrial Metabolism (2) MMP (5) MOFs (1) Nectin-4 (1) NF-κB (1) Orphan GPCR (1) PD-1/PD-L1 (2) PERK (1) PI3K (1) PKC (5) Potassium Channel (2) Prostaglandin Receptor (1) PROTACs (1) Proteasome (3) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (16) Reactive Oxygen Species (ROS) (3) Reference Standards (4) Sirtuin (2) Small Interfering RNA (siRNA) (3) Sodium Channel (1) Somatostatin Receptor (1) Target Protein Ligand-Linker Conjugates (2) Tau Protein (1) Thrombin (1) Thrombopoietin Receptor (2) Toll-like Receptor (TLR) (1) Topoisomerase (7) Transferrin Receptor (1) Transmembrane Glycoprotein (3) TRP Channel (2) ULK (1) VEGFR (2) Wnt (2) YAP (1) β-catenin (2)
By Research Areas:	Cancer (145) Cardiovascular Disease (20) Endocrinology (1) Infection (25) Inflammation/Immunology (26) Metabolic Disease (6) Neurological Disease (16)
Click Chemistry:	DBCO (1) Azide (2) BCN (1)
Oligonucleotides:	Pegylated Lipids (14) Phospholipids (1) siRNA drugs (2) Polymers (1) siRNAs (2)

280

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

124

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13631E

Deruxtecan Maximum Cited Publications 25 Publications Verification MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1351

Angiopep-2-Cys	Biochemical Assay Reagents	Cancer
Angiopep-2-cys is a conjugate of Angiopep-2 hydrochloride (HY-P2341) and cysteine. Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer .

HY-147239

MC-VA-PABC-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-VA-PABC-MMAE is a *agent-linker conjugate* for ADC*. MC-VA-PABC-MMAE contains the ADCs linker (peptide* MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-43869

Vipivotide tetraxetan Ligand-Linker Conjugate PSMA-617 Ligand-Linker conjugate	ADC Linker	Cancer
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .

HY-15938

5-FAM SE	Fluorescent Dye	Others
5-FAM SE is a single isomer, is a fluorescent labeling reagent used for labeling peptides, proteins and nucleotides. 5-FAM SE can react with amines and can yield stable amine conjugates .

HY-150241

DOPE-NHS	Exosomes Biochemical Assay Reagents Liposome	Others
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .

HY-P4198

Fmoc-N(Me)-Sar10 Fmoc-Sar10	Biochemical Assay Reagents	Others
Fmoc-N(Me)-Sar10 (Fmoc-Sar10) is an Fmoc-protected derivative of a methylated sarcosine decamer, which supports cell adhesion, proliferation, and maintenance of cell phenotype. Fmoc-N(Me)-Sar10 is primarily used in peptide synthesis to introduce enzymatically stable spacer sequences. By mimicking the extracellular matrix (ECM), Fmoc-N(Me)-Sar10 provides a 3D growth microenvironment for cells and is mainly used in tissue engineering and 3D cell culture, particularly suitable for in vitro culture studies of cells such as chondrocytes .

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-D1872

800CW NHS ester	Fluorescent Dye	Others
800CW NHS ester is a near-infrared fluorescent dye active ester that can conjugate with amine-containing small molecules, antibodies, peptides, and other substances to form fluorescent conjugates. 800CW NHS ester exhibits high fluorescence quantum yield and low non-specific binding properties. 800CW NHS ester can be used in biomedical research such as microbial infection imaging, tumor imaging, and biochemical detection .

HY-P11051

GE11, Cys Conjugated	Biochemical Assay Reagents	Cancer
GE11, Cys Conjugated is a peptide conjugate. GE11, Cys Conjugated consists of GE11 (HY-P10128) conjugated to a GGGGC sequence. GE11, Cys Conjugated can be used to synthesize stimulus-responsive peptide nanomaterials (SRPNs) for photoacoustic imaging and cancer research, such as studies on triple-negative breast cancer (TNBC) .

HY-P10646

Muscle homing peptide M12	Biochemical Assay Reagents	Neurological Disease
Muscle homing peptide M12 can preferentially bind to surface protein of muscle cells. Muscle homing peptide M12 mediates enhanced cellular uptake of nanoparticles (NPs) in myoblasts in vitro. Muscle homing peptide M12 is covalently conjugated to PLGA-PEG NPs via the N-terminal α-amino groups of peptides using the N-hydroxysuccinimide ester reaction .

HY-P11099

Cys-LT7	Transferrin Receptor	Neurological Disease Cancer
Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-164166

Fmoc-Sar-Sar-Sar-OH	Biochemical Assay Reagents Drug Intermediate Amino Acid Derivatives	Others
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of agent-peptide ligand conjugates .

HY-P3815

Casein Kinase 2 Substrate Peptide 2 Publications Verification	Casein Kinase	Others
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .

HY-160807

DBM-GGFG-NH-O-CO-Exatecan	Drug-Linker Conjugates for ADC	Cancer
DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-100566

SuO-Val-Cit-PAB-MMAE 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SuO-Val-Cit-PAB-MMAE is a *agent-linker conjugate* for ADC** by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .

HY-19813A

mDPR-Val-Cit-PAB-MMAE TFA	Drug-Linker Conjugates for ADC	Cancer
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition ^{[1] ^.}

HY-169322

APL-1081 Mal-Exo-EVC-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
APL-1081 (Mal-Exo-EVC-MMAE) is part of an antibody-conjugated active molecule (ADC). APL-1081 is conjugated with an ADC linker (peptide Mal-Exo-EEVC) and a potent tubulin polymerization inhibitor, MMAE (HY-15162) .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .

HY-44177

Val-Cit-PAB-MMAF sodium	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF sodium is a *drug-Linker conjugate* for ADC*. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide* Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P1043

NGR peptide 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .

HY-W717743

DOTAM-mono-acid	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
DOTAM-mono-acid is a chelator with DOTAM as its core. DOTAM-mono-acid contains a carboxylic acid group that can be activated to form an amide bond with the N-terminus of a peptide. DOTAM-mono-acid can form peptide conjugates for radiometal labeling .

HY-P4091

LSD	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P1188

LDV-FITC	Integrin	Cancer
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (K_d: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .

HY-W012166

N-Succinimidyl bromoacetate NHS-Bromoacetate	Biochemical Assay Reagents	Infection
N-Succinimidyl bromoacetate (NHS-Bromoacetate) is a heterobifunctional crosslinking reagent, mainly used to modify the ɛ-amino group of lysine side chains. By covalently linking its bromoacetyl moiety to the ɛ-amino group of lysine in peptidomimetics, N-Succinimidyl bromoacetate enables their conjugation with thiol-modified nanoparticles via thioether bonds. N-Succinimidyl bromoacetate also performs bromoacetylation modification on carrier proteins, which then forms stable thioether bonds with the thiol groups of cysteine in peptides, thus efficiently preparing soluble peptide-protein conjugates with high substitution ratios. N-Succinimidyl bromoacetate can be used to prepare activated Sepharose derivatives for affinity chromatography, protein affinity labeling reagents, and peptide-protein immunogen conjugates with non-immunogenic linkages. N-Succinimidyl bromoacetate is applicable to studies related to HIV-1 infection and glioblastoma multiforme .

HY-129360

Ala-Ala-Asn-PAB	ADC Linker	Cancer
Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-153395

PH-HG-005-5	Drug-Linker Conjugates for ADC	Cancer
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .

HY-177205

DSPE-PEG2000-CRPPR	Biochemical Assay Reagents	Others
DSPE-PEG2000-CRPPR is a polyethylene glycol (PEG) conjugate composed of DSPE and Heart-homing peptide (CRPPR) (HY-P10641). DSPE-PEGs are modified with the CRPPR peptide to bind cysteine-rich protein 2 (CRIP2) as well as FITC-labeled superparamagnetic iron oxide nanoparticles .

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .

HY-172273A

DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY	Liposome	Cancer
DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .

HY-101909

Val-Cit-PAB-MMAF	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF is a *drug-Linker conjugate* for ADC. Val-Cit-PAB-MMAF is composed of an ADC linker** (peptide Val-Cit-PAB) and a potent microtubule polymerization inhibitor MMAF (HY-15579) .

HY-132164

Gly-7-MAD-MDCPT	ADC Payload Topoisomerase	Cancer
Gly-7-MAD-MDCPT (compound 4b) is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin (HY-16560) compound, it shows cytotoxicity to various cancer cells with IC₅₀ values of 10-1000 nM .

HY-147021

MC-Val-D-Cit-PAB-PNP	ADC Linker	Cancer
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.

HY-P1043A

NGR peptide Trifluoroacetate 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P10183

CD36 Peptide P (139-155), Cys conjugated Cys-CD36(139-155)	Transmembrane Glycoprotein	Inflammation/Immunology
CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5 .

HY-P10559

(RXR)4XB	Bacterial	Infection
(RXR)4XB is a cell-penetrating peptide, that binds the phosphorodiamidate morpholino oligomers (PMOs), forms peptide-conjugated PMOs (PPMOs), and improves the delivery of PMO into bacterial cells. (RXR)4XB-PMO conjugate prevents the formation of biofilms, inhibits Pseudomonas aeruginosa with MIC₅₀ of 0.5 to 16 μM, and reduces the bacterial burden in mouse acute pneumonia models .

HY-P3364

Ac-QPKK(Ac)-AMC	Fluorescent Dye Sirtuin HDAC	Others
Ac-QPKK(Ac)-AMC is a p53-derived peptide conjugated with a fluorophore, which serves as a fluorescent peptide substrate for detecting the deacylase activity of zinc-dependent HDACs and sirtuins (Ex = 360 nm; Em = 460 nm) .

HY-P10701

Q11 peptide	Biochemical Assay Reagents	Inflammation/Immunology Cancer
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .

HY-161564

T4/OVA	Biochemical Assay Reagents	Inflammation/Immunology
T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells .

HY-P10895

HR97 TFA	Biochemical Assay Reagents	Others
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-158199

BCN-HS-PEG2-bis(PNP)	ADC Linker	Cancer
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .

HY-172273

DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY	Liposome	Cancer
DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .

HY-P11205A

Cys-PKHB1 TFA Cys-txCD47 TFA	CD47 Reactive Oxygen Species (ROS) Thrombopoietin Receptor	Inflammation/Immunology Cancer
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca ⁺ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death .

HY-W738256

Maleimide-DTPA MDTPA	Radionuclide-Drug Conjugates (RDCs)	Cancer
Maleimide-DTPA (MDTPA) is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA is a good material for medical imaging or treatment.

HY-P10946

FAP targeting peptide-PEG2 conjugate	Radionuclide-Drug Conjugates (RDCs)	Cancer
FAP targeting peptide-PEG2 conjugate (Example A1) is the peptide (HY-P10945) and linker conjugate of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15721

Tryptophan-cholic acid Trp-CA	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	Orphan GPCR GLP Receptor
Tryptophan-cholic acid (Trp-CA) is a microbial *amino acid-conjugated* bile acid that acts as an endogenous ligand and agonist (EC₅₀=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1**, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D) .

HY-113469

Cyclic GMP 1 Publications Verification	Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Animals Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-113469A

Cyclic GMP sodium 1 Publications Verification	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-113469R

Cyclic GMP (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-113469AR

Cyclic GMP sodium (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Cyclic GMP sodium (Standard) is the analytical standard of Cyclic GMP sodium (HY-113469A). This product is intended for research and analytical applications. Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

Cat. No.	Product Name	Chemical Structure

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES3

Deruxtecan-d2
Deruxtecan-d₂ is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-15582S

Auristatin E-d8

Auristatin E-d₈ is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES2

Deruxtecan-d4-1
Deruxtecan-d₄-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-W767865

Cyclic GMP sodium-13C5

Cyclic GMP sodium- ¹³C₅ is the ¹³C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-W654000

Cyclic GMP-13C,15N2

Cyclic GMP- ¹³C, ¹⁵N₂ is ¹³C and ¹⁵N labeled Cyclic GMP (HY-113469). Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

Targets Recommended: RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100374G

Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-13631EG

Deruxtecan MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks